Serine/threonine kinase inhibitors
US10519126B2 · kind B2 · utility
0Cited by
10References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 16, 2017 |
| Grant date | Dec 31, 2019 |
| Priority date | — |
| Expiry date | Jun 16, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.